Compare Ascendis Pharma A/S (ASND) vs Cincinnati Financial Corporation (CINF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Cincinnati Financial Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Cincinnati Financial Corporation trades at $180.5 (market cap $27.73B). The key difference: Cincinnati Financial Corporation is the larger of the two by market cap, and Cincinnati Financial Corporation pays a 2.1% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CINF | |
|---|---|---|
Market Cap | $17.74B | $27.73B |
Sector | Health | Financials |
52-Week High | $277.18 | $192.03 |
52-Week Low | $163.32 | $145.80 |
Enterprise Value | $18.11B | $27.41B |
Dividend Yield | — | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
CINF trades at $179.28, up 2.19% today, near its consensus price target of $185.75. The stock shows strong fundamentals with a P/E of 10.25, net income margin of 21.33%, and consistent earnings beats in recent quarters. Technical indicators are bearish overall, with the current price near the pivot point of $178. Recent news highlights a scheduled Q2 2026 earnings webcast and a 65-year dividend streak, with a $0.94 dividend paid in July 2026.
Outlook remains positive due to valuation appeal and earnings momentum, but risks include technical bearish signals and exposure to catastrophe losses. Revenue growth is steady, projected to reach $12.9B in 2026, supporting a bullish analyst consensus despite mixed technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →
